Michael Wolff Jensen - 18 Mar 2026 Form 3 Insider Report for Ascendis Pharma A/S (ASND)

Role
EVP, Chief Legal Officer
Signature
/s/ Michael Wolff Jensen
Issuer symbol
ASND
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 18:12:58 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
JENSEN MICHAEL WOLFF EVP, Chief Legal Officer C/O ASCENDIS PHARMA A/S, TUBORG BOULEVARD 12, HELLERUP, DENMARK /s/ Michael Wolff Jensen 18 Mar 2026 0001965622

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ASND Warrants 18 Mar 2026 Ordinary Shares 30,000 $62.17 Direct F1
holding ASND Warrants 18 Mar 2026 Ordinary Shares 27,000 $108.00 Direct F1
holding ASND Warrants 18 Mar 2026 Ordinary Shares 22,755 $176.28 Direct F1
holding ASND Warrants 18 Mar 2026 Ordinary Shares 14,504 $139.65 Direct F1
holding ASND Restricted Stock Units 18 Mar 2026 Ordinary Shares 4,246 Direct F2, F3
holding ASND Restricted Stock Units 18 Mar 2026 Ordinary Shares 3,197 Direct F3, F4
holding ASND Restricted Stock Units 18 Mar 2026 Ordinary Shares 9,552 Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The warrants are fully vested and currently exercisable.
F2 The restricted stock units vest on March 1, 2027 and have no expiration date.
F3 Each restricted stock unit represents a contingent right to receive one ADS.
F4 The restricted stock units vest in two equal annual installments beginning on March 1, 2027.
F5 The restricted stock units vest in three equal annual installments beginning on March 1, 2027.